TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been launched in China.

东京和马萨诸塞州剑桥，2024年6月27日（环球通讯社）--卫材株式会社（总部：东京，首席执行官：内藤春夫，“卫材”）和Biogen Inc.（纳斯达克：BIIB，公司总部：马萨诸塞州剑桥，首席执行官：克里斯托弗·维赫巴赫，“Biogen”）今天宣布，人源化抗可溶性聚集淀粉样蛋白β（Aβ）单克隆抗体“LEQEMBI®”（中国商标名：“乐，通用名：lecanemab）已在中国推出。

LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain.

LEQEMBI于2024年1月获得批准，用于治疗阿尔茨海默病（AD）和轻度AD痴呆引起的轻度认知障碍（MCI）。中国是继美国和日本之后第三个推出LEQEMBI的国家。。

LEQEMBI is the world’s first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. Eisai estimates there will be 17 million patients with MCI or mild dementia due to AD (collectively referred to as early AD) in China in 2024, which is expected to increase as the population ages.

LEQEMBI是世界上第一个也是唯一一个被批准的治疗方法，通过这种机制可以降低疾病进展速度，减缓认知和功能下降。卫材估计，到2024年，中国将有1700万MCI或轻度痴呆患者因AD（统称为早期AD）而患病，预计随着人口老龄化，这一数字将增加。

Eisai is distributing the product in China and conducting information provision activities through specialized Medical Representatives, while also working to build a unique early AD diagnosis and treatment pathway that combines online and offline services. In collaboration with commercial health insurance companies, private health checkups, and nursing homes, Eisai will widely provide disease awareness and pre-screening opportunities and encourage high-risk individuals to visit specialized hospitals early or refer them t.

卫材在中国销售该产品，并通过专业医疗代表开展信息提供活动，同时还致力于建立一个独特的早期AD诊断和治疗途径，将线上和线下服务结合起来。卫材将与商业健康保险公司、私人健康检查和疗养院合作，广泛提供疾病意识和预筛查机会，并鼓励高危人群尽早前往专科医院或转诊。